AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Lifecare ASA

Share Issue/Capital Change Oct 18, 2024

3654_rns_2024-10-18_2f0c4a2d-b818-44fd-a38d-2a09a838ca08.pdf

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

LIFECARE ASA: SHARE CAPITAL INCREASE REGISTERED

Reference is made to the stock exchange announcement made by Lifecare ASA (the "Company") on 15 October 2024 regarding the successful results of the retail offering (the "Offering") of 831,266 new shares (the "Offer shares") in the Company, raising gross proceeds of NOK 16.6 million.

The share capital increase pertaining to the issuance of the new shares in the Offering has now been registered with the Norwegian Register of Business Enterprises. The Company's new share capital is NOK 82,435,490.80 divided into 15,852,979 shares, each with a nominal value of NOK 5.20.

The Offer Shares are expected to be delivered to applicants in the VPS on or about 22 October 2024, subject to timely payment having been received. The Offer Shares will be tradable following delivery of the Offer Shares to applicants in the VPS, expected on or about 22 October 2024. The Company's shares, including the Offer Shares, are expected to become tradable on Oslo Børs on or about 22 October 2024.

About us

Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") on the sensor body for read-out of pressure variations. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, [email protected], +47 40 05 90 40

Renete Kaarvik, CFO, [email protected], +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities Trading Act, §5-12. The information was submitted for publication at 2024-10-18 10:59 CEST.

Talk to a Data Expert

Have a question? We'll get back to you promptly.